What to know about COVID-19 study that was finally published after being blocked by CDC
COVID-19 Study Reaches Public After CDC Delay
What to know about COVID 19 study - A groundbreaking study assessing the efficacy of the 2025-26 COVID-19 vaccine was finally released on Tuesday, following its initial exclusion from a federal government update. The research, spearheaded by scientists at the Centers for Disease Control and Prevention (CDC) and collaborators from across the United States, focused on the vaccine’s impact on adults aged 18 and above who do not have compromised immune systems. Conducted during the fall and winter of 2025, the findings suggested that the updated vaccine significantly reduced the risk of hospitalization by 55% and emergency department or urgent care visits for COVID-19 symptoms by 50% compared to individuals who did not receive the shot.
The study’s publication came after a delay, with the CDC initially withholding its inclusion in the Morbidity and Mortality Weekly Report. This report, which typically summarizes key public health data, was meant to feature the findings in March. The authors emphasized that the research did not account for prior COVID-19 infections or earlier vaccine doses, which could influence the results. They acknowledged that the study’s findings might reflect the additional protection provided by the 2025-26 vaccine over existing immunity, though this limitation was noted as a factor in interpreting the data.
Dr. Peter Hotez, a professor and dean at the National School of Tropical Medicine at Baylor College of Medicine, expressed surprise at the CDC’s decision to block the study. “The head scratcher is why CDC would block [the study],” he told ABC News. “If anything, what they should be doing to encourage vaccination is sharing all evidence of effectiveness so the public can stay informed. Blocking the report seems to contradict the goal of promoting public health.”
Methodology Under Scrutiny
At the heart of the controversy was the study’s use of a test-negative design, a method that compares individuals who test positive for a disease with those who test negative. This approach, commonly employed in observational studies, allows researchers to evaluate real-world vaccine effectiveness without relying on a single, comprehensive healthcare database. Dr. Jay Bhattacharya, acting director of the CDC and head of the National Institutes of Health, had previously raised concerns about this methodology in an April op-ed for The Washington Post. He argued that the test-negative design could introduce biases, such as overrepresenting cases where individuals seek medical care for symptoms.
Despite these critiques, the study’s authors maintained that the test-negative framework was suitable for their analysis. They pointed out that the method had been used effectively in prior research, including studies published in JAMA Network Open. “We’ve been using test-negative design for years to answer questions like this,” said Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia. “When critics, like those in the administration, say it’s flawed, they should specify why. Otherwise, it’s just a way to cast doubt on the evidence.”
Public Health Debate
While the CDC’s concerns about methodology were valid, some experts questioned whether the blockage was an overreaction. The study’s findings aligned with previous research showing that vaccination reduces the risk of severe illness. However, the authors acknowledged limitations, such as potential misclassification of hospital visits and incomplete vaccination records. These factors could have affected the analysis, particularly in cases where hospitalization rates were low or data collection was inconsistent.
Emily Hillard, a spokesperson for the Health and Human Services (HHS), defended the CDC’s decision in a statement to ABC News. She stated, “When questions arise about methodology, we address them directly. Responsible science requires careful review. Taking time to ensure analyses are methodologically sound and clearly communicated is always preferable to risking error.” The HHS emphasized that the CDC does not base conclusions on predetermined outcomes but evaluates the weight of evidence through rigorous methods, communicates uncertainties, and subjects its work to scientific scrutiny before publication.
Public health advocates argue that the test-negative design, while not perfect, remains a valuable tool in the absence of a centralized healthcare database. The method helps track real-world effectiveness by leveraging data from patients who seek care for symptoms, providing insights into how vaccines perform in diverse populations. Dr. Offit highlighted this, saying, “The CDC’s approach to methodology is reasonable, but they need to explain the specific issues with this study to justify blocking its release.”
Context and Implications
The study’s delayed publication has sparked broader discussions about transparency in scientific communication. While the CDC maintains that its review process is thorough, critics suggest the blockage may have been motivated by a desire to control the narrative around vaccine effectiveness. This comes amid ongoing debates about vaccine safety and efficacy, particularly in the wake of the FDA’s decision to withdraw earlier publication of related findings on the shingles vaccine. The situation has also been tied to recent HHS firings and questions about the administration’s stance on vaccine research.
For the public, the study’s release is a critical step in understanding how vaccines perform in the evolving pandemic landscape. The 55% and 50% reductions in hospitalization and emergency visits, respectively, offer concrete data to support vaccination efforts. However, the controversy surrounding the CDC’s initial delay underscores the importance of clear communication in maintaining trust. As Dr. Hotez noted, “When people in positions of authority block studies that show positive outcomes, it can create confusion. The goal should be to provide accurate, accessible information to guide health decisions.”
The debate over the study’s methodology highlights the balance between scientific rigor and public engagement. While the test-negative design has its drawbacks, it remains a practical solution for analyzing vaccine effectiveness in the absence of perfect data. The CDC’s actions have prompted calls for greater transparency, with some experts suggesting that the agency should prioritize sharing findings that support public health goals over delaying their release. As the 2025-26 vaccine rollout continues, the study’s results will likely play a key role in shaping vaccination policies and public perception of the vaccine’s benefits.
Broader Impact on Vaccination Campaigns
With the study now published, health officials have a new dataset to bolster their arguments for continued vaccination. The findings reinforce the importance of booster shots in reducing severe outcomes, especially as the virus evolves. However, the delay in publication raises questions about how promptly scientific information is disseminated during public health emergencies. Dr. Offit stressed that the methodology, while imperfect, is a standard tool in epidemiology and should not be dismissed without careful examination.
As the pandemic progresses, the ability to quickly share and analyze data becomes increasingly vital. The CDC’s initial blockage of the study, combined with its methodological critiques, has drawn attention to the challenges of maintaining scientific objectivity while addressing political or public concerns. The study’s release on Tuesday marks a significant moment, but its impact will depend on how effectively the CDC and other health agencies communicate its findings to the public. In the meantime, the data provides a crucial reminder of the vaccine’s role in mitigating the spread and severity of COVID-19, even in the face of ongoing debates about its effectiveness.
Ultimately, the study’s publication underscores the dynamic nature of public health research. While the CDC’s review process is essential for ensuring accuracy, the delay in sharing results highlights the need for a more transparent and responsive approach. The 55% and 50% effectiveness rates, though subject to interpretation, offer clear evidence that the 2025-26 vaccine is effective in preventing serious illness. As the scientific community continues to analyze the data, the hope is that these findings will be used to inform and strengthen vaccination efforts, ensuring that the public has access to the most reliable information available.